The WHO declared mpox a global public health emergency for the second time in two years in August, following the emergence of a new variant that spread from the Democratic Republic of Congo to neighboring countries. The viral infection, which typically causes flu-like symptoms and pus-filled skin lesions, has particularly affected children, adolescents, and individuals with weakened immune systems.
In September, the WHO approved Jynneos as the first mpox vaccine for adults, easing vaccine access in countries hardest hit by the virus. The latest decision to extend approval to adolescents comes after the European Union had already given its nod for the age group in the same month.
